Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for...
First Patient Enrolled in P-321-202 Clinical Trial Durham, NC (July 26, 2016) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced...
View ArticleParion Sciences Announces Presentation of Clinical Data with Novel Pulmonary...
Clinical Data to be presented for a novel device for transnasal delivery of a pulmonary aerosol in children with Cystic Fibrosis Durham, NC (October 25, 2016) – Parion Sciences, a company dedicated to...
View ArticleTopical ENaC blocker serves as novel approach to tear film
First-in-human trial encouraging, identifies agent that is associated with signs of improvement in tear function READ THE FULL ARTICLE HERE ►
View ArticleShire and Parion Sciences Enter into a Collaborative License Agreement to...
Demonstrates ongoing commitment to innovation in ophthalmics for Shire P-321 is a Phase 2 investigational topical treatment for dry eye disease Lexington, Massachusetts, and Durham, North Carolina, US...
View ArticleParion Sciences and Takeda End Collaboration on P-321 for Ophthalmic Indications
Durham, North Carolina – October 31, 2019 – Parion Sciences, Inc. today announced the termination of the License Agreement dated April 28, 2017 between Parion and Shire (now Takeda Pharmaceutical...
View ArticleParion Sciences Reacquires Rights to Epithelial Sodium Channel Inhibitors
Durham, NC (January 23, 2020) – Parion Sciences, a company dedicated to the development of novel treatments for pulmonary diseases, announced today that it has reached an agreement with Vertex...
View ArticleFDA Grants Orphan Drug Designation, Fast Track Designation and Rare Pediatric...
Company Release July 29, 2020 Durham, NC. Parion Sciences, Inc. (“Parion”), a clinical-stage pharmaceutical company focused on treatments of unmet respiratory diseases, announced today that the U.S....
View ArticleParion Sciences P‐1037 Inhalation Solution receives Orphan Drug Designation...
Company Release November 17, 2020 Durham, NC. Parion Sciences, Inc. (Parion), a clinical-stage pharmaceutical company focused on treatments of unmet respiratory diseases, announced today, that on...
View ArticleParion Sciences Receives Positive Opinion from EMA Paediatric Committee on...
Durham, NC, April 5, 2023 Parion Sciences (Parion) today announced receipt of a positive opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) for the Paediatric...
View ArticleParion Sciences Announces Publication of Phase 2 CLEAN-PCD Study in The...
Durham, NC (September 8, 2023) – Parion Sciences Inc. today announced publication in The Lancet Respiratory Medicine of positive results of the Phase 2 study of idrevloride in hypertonic saline in...
View Article